Maravai Lifesciences Holdings, Inc.
MRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001823239
No open-market purchases or sales by Maravai Lifesciences Holdings, Inc. insiders were filed in the last 90 days; 177 institutions reported holding it in 13F filings for Q2 2026, worth $875.5M in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +21 vs. previous quarter
- 177
- 13F valueReported value at the end of Q2 2026
- $875.5M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $185.7M
- −28.3% year over year
- Net income, FY2025
- -$130.8M
- No comparable prior period
- Free cash flow, FY2025
- -$70.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $45.9M
- +10.1% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $130.8M (70.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 14.1M
- Shares sold short
- Change
- +705.0K
- +5.3% vs. previous
- Days to cover
- 6.81
- At average daily volume
Superinvestors holding MRVI, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding MRVI at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Maravai Lifesciences Holdings, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2026 (view filing) | Jun 9-10 | 1 day | Oreshack KurtGeneral Counsel | SSaleClass A Common Stock | −50.0K | $5.08 | −$254.0K | −13.0%335.8K after | 2 lots10b5-1 |
| Dec 9, 2025 (view filing) | Dec 5-8 | 4 days | Lucier Gregory TDirector | PPurchaseClass A Common Stock | +100.0K | $3.69 | +$368.5K | +181.4%155.1K after | 2 lots |
| Nov 17, 2025 (view filing) | Nov 13 | 4 days | Brust BerndChief Executive Officer | PPurchaseClass A Common Stock | +216.2K | $3.25 | +$702.7K | +86.3%466.8K after | |
| Nov 13, 2025 (view filing) | Nov 11-12 | 2 days | Brust BerndChief Executive Officer | PPurchaseClass A Common Stock | +250.6K | $3.23 | +$809.0K | New position250.6K after | 2 lots |
| Jan 31, 2025 (view filing) | Jan 31 | Same day | Oreshack KurtGeneral Counsel | SSaleClass A Common Stock | −25.0K | $5.03 | −$125.8K | −13.0%167.6K after | 10b5-1 |
| Nov 14, 2024 (view filing) | Nov 12 | 2 days | DeFord John ADirector | PPurchaseClass A Common Stock | +17.5K | $5.75 | +$100.6K | +33.3%70.0K after | |
| Nov 12, 2024 (view filing) | Nov 11 | 1 day | Hull CarlSee Remarks | PPurchaseClass A Common Stock | +175.0K | $5.64 | +$987.0K | New position175.0K after | |
| May 30, 2024 (view filing)5:39 PM ET | May 28 | 2 days | GTCR Co-Invest XI LP and 7 othersDirector, 10% Owner | SSaleClass A common stock | −9.94M | $9.82 | −$97.6M | −33.0%20.2M after |
Top 10 13F holders, Q2 2026
See all 177 holdersThe largest institutional positions in Maravai Lifesciences Holdings, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| GTCR LLC | 20,150,005 | $125.7M | 3.22% | 00.0% | Unchanged |
| BlackRock, Inc. | 9,970,780 | $62.2M | 0.00% | +625,512+6.7% | Added |
| Braidwell LP | 8,702,921 | $54.3M | 2.01% | −1,537,243−15.0% | Reduced |
| 12 West Capital Management LP | 7,060,195 | $44.1M | 8.24% | −200,000−2.8% | Reduced |
| Millennium Management LLC | 6,508,220 | $40.6M | 0.03% | +4,858,730+294.6% | Added |
| Vanguard Capital Management LLC | 5,283,665 | $33.0M | 0.00% | −166,037−3.0% | Reduced |
| Ophir Asset Management Pty Ltd | 4,826,698 | $30.1M | 2.48% | +4,826,698 | New |
| Renaissance Technologies LLC | 4,606,491 | $28.7M | 0.04% | +341,802+8.0% | Added |
| Deutsche Bank AG | 4,304,927 | $26.9M | 0.01% | +3,446,672+401.6% | Added |
| First Eagle Investment Management, LLC | 3,671,287 | $22.9M | 0.04% | +1,146,951+45.4% | Added |
Holders of 5% or more of MRVI
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Maravai Lifesciences Holdings, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 5.90%8.58M shares | – | Oct 22, 20243 filings | Oct 17, 2025 | SEC |
| Millennium Management LLC | 13G | 5.20%7.77M shares | +0.50 ppfrom 4.70% | Oct 26, 20238 filings | Sep 29, 2026 | SEC |
Politician trades
All politician trades in MRVI1 member of Congress reported 1 trade in Maravai Lifesciences Holdings, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| May 19, 2023 |  Daniel S. Goldman House · NY | Sell | $1K-$15K |
House · NY · May 19, 2023
Sell$1K-$15K